Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02290665 · ClinicalTrials.gov registry record · NA
Localized Therapeutics for the Treatment of Gastrointestinal Disorders
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT02290665: Completed NA study, sponsored by Stanford University.
NCT02290665 is a NA study that has completed, run by Stanford University. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02290665, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the patient preference for a biocompatible thermosensitive solution-gel versus water or saline (liquid) enema. The thermosensitive solution-gel is comprised of poloxamer, an inactive compound that is designated as GRAS (generally recognized as safe) by FDA. It could subsequently be used as a medium for drug delivery. The poloxamer (gel) is administered to study participants in order to assess preference and proximal distribution.
Interventions
- OTHER Saline enema
- OTHER Thermosensitive gel rectal formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2015-01-30 |
| Est. Completion | 2015-09-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02290665
The ClinicalTrials.gov registry entry for NCT02290665 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline enema is the first listed.
NCT02290665 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02290665 about?
NCT02290665 is a clinical study titled "Localized Therapeutics for the Treatment of Gastrointestinal Disorders". The purpose of this study is to determine the patient preference for a biocompatible thermosensitive solution-gel versus water or saline (liquid) enema. The thermosensitive solution-gel is comprised of poloxamer, an inactive compound that is designated as GRAS (generally recognized as safe) by FDA. ...
What is the current status of trial NCT02290665?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2015-01-30. Estimated completion is 2015-09-28.
What interventions are being tested in trial NCT02290665?
The interventions under investigation include: Saline enema (OTHER), Thermosensitive gel rectal formulation (OTHER).
Who is sponsoring clinical trial NCT02290665?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.